We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Study: Small Policy Changes Could Prevent Branded ‘Evergreening’
Study: Small Policy Changes Could Prevent Branded ‘Evergreening’
April 24, 2012
The FDA could require drugmakers seeking NDA approval on new formulations or doses on previously approved molecules to resolve outstanding patent litigation before a new approval is granted to prevent “evergreening,” or delaying of generic competition.